Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. The Leukemia Working Party of the European Group of Bone Marrow Transplantation (EBMT)
- PMID: 1628128
Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. The Leukemia Working Party of the European Group of Bone Marrow Transplantation (EBMT)
Abstract
The prognostic value of diagnosis-remission interval on leukemia-free survival (LFS) after bone marrow transplantation (BMT) was investigated retrospectively in 193 adult patients with acute lymphoblastic leukemia (ALL) transplanted in first remission and reported to the EBMT between 1979 and 1986. Patients achieving remission within 8 weeks of diagnosis ('fast responders') had better LFS after BMT than those with remission after 8 weeks ('slow responders'): LFS at 3 years was 43% vs 32% for fast and slow responders, respectively (p = 0.04). The effect on LFS was particularly severe for slow responders transplanted within 3 months of remission. Only 17% of the slow responders with short remission-BMT interval survived at 3 years. Decreased LFS was caused by both excess of transplant-related mortality and increased relapse incidence. In a multivariate analysis, time intervals (both diagnosis-remission and remission-BMT) were the strongest independent prognostic factor for LFS, probability of relapse and transplant-related mortality. We conclude that the intervals diagnosis-remission and remission-BMT have a strong prognostic value in adult patients with ALL not only for remission duration after conventional treatment, but also for LFS after BMT.
Similar articles
-
Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).Bone Marrow Transplant. 1996 Jan;17(1):13-8. Bone Marrow Transplant. 1996. PMID: 8673048
-
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.J Clin Oncol. 2004 Feb 1;22(3):416-23. doi: 10.1200/JCO.2004.06.102. Epub 2003 Dec 22. J Clin Oncol. 2004. PMID: 14691124
-
Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant. 1996 Jul;18(1):111-7. Bone Marrow Transplant. 1996. PMID: 8832003
-
European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT).Bone Marrow Transplant. 1994 Aug;14(2):293-8. Bone Marrow Transplant. 1994. PMID: 7994245 Review.
-
Trisomy 8 in acute lymphoblastic leukemia (ALL): a case report and update of the literature.Leukemia. 1990 Oct;4(10):717-9. Leukemia. 1990. PMID: 2214875 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical